Effects of Selenium treatment on cardiac function in Chagas heart disease: Results from the STCC randomized Trial.

Background: Chagas disease (caused by infection) evolves to chronic chagasic cardiomyopathy (CCC) affecting 1.8 million people worldwide. This is the first randomized, placebo-controlled, double-blinded, clinical trial designed to estimate efficacy and safety of selenium (Se) treatment in CCC.

A protocol update for the Selenium Treatment and Chagasic Cardiomyopathy (STCC) trial.

Unlabelled: Several studies evaluating clinical forms of chronic Chagas disease show that about one-third of patients present cardiac involvement. Heart failure, sudden death and cardioembolic stroke are the main mechanisms of death in Chagas heart disease. The impact of specific etiologic treatment on the prognosis of patients with chronic Chagas heart disease is very limited regardless of the presence or absence of heart failure.